BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 14870836)

  • 21. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant aromatase inhibitors: are we there yet?
    Fleming GF
    Cancer; 2003 Nov; 98(9):1779-81. PubMed ID: 14584057
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety of aromatase inhibitors in the adjuvant setting.
    Perez EA
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    Vakaet L
    J Natl Cancer Inst; 2006 Aug; 98(16):1162; author reply 1162-3. PubMed ID: 16912269
    [No Abstract]   [Full Text] [Related]  

  • 25. Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
    Higa GM
    Drugs; 2006; 66(3):363-4. PubMed ID: 16526828
    [No Abstract]   [Full Text] [Related]  

  • 26. A decade of letrozole: FACE.
    O'Shaughnessy J
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anastrozole data show continued delay in relapse, but no clear survival advantage.
    Travis K
    J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
    Mouridsen H; Gershanovich M
    Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
    Piccart MJ; Cardoso F; Atalay G
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S52-4. PubMed ID: 12409074
    [No Abstract]   [Full Text] [Related]  

  • 30. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current role of endocrine therapy in the management of breast cancer.
    Robertson JF
    Breast Cancer; 2002; 9(4):276-81. PubMed ID: 12459706
    [No Abstract]   [Full Text] [Related]  

  • 32. Aromatase inhibitors and their use in the sequential setting.
    Coombes RC; Harper-Wynne C; Dowsett M
    Endocr Relat Cancer; 1999 Jun; 6(2):259-63. PubMed ID: 10731118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer studies challenge tamoxifen therapy.
    Timms B
    Lancet Oncol; 2000 Nov; 1():132. PubMed ID: 11905647
    [No Abstract]   [Full Text] [Related]  

  • 34. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
    Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New aromatase inhibitors in the treatment of advanced breast cancer.
    Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M
    Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-operative endocrine therapy for postmenopausal women: when and why?
    Tondini C; Fenaroli P; Labianca R
    Ann Oncol; 2001 Nov; 12(11):1505-6. PubMed ID: 11822746
    [No Abstract]   [Full Text] [Related]  

  • 37. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
    Dixon JM; Love CD; Renshaw L; Bellamy C; Cameron DA; Miller WR; Leonard RC
    Endocr Relat Cancer; 1999 Jun; 6(2):227-30. PubMed ID: 10731113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A summary of second-line randomized studies of aromatase inhibitors.
    Buzdar AU
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):109-14. PubMed ID: 11850214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of aromatase inhibitors in breast carcinoma.
    Santen RJ; Harvey HA
    Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.